We analyzed HIV-1 genome sequences from 68 newly infected volunteers in the STEP HIV-1 vaccine trial. To determine whether the vaccine exerted selective T cell pressure on breakthrough viruses, we identified potential T cell epitopes in the founder sequences and compared them to epitopes in the vaccine. We found greater distances to the vaccine sequence for sequences from vaccine recipients than from placebo recipients. The most significant signature site distinguishing vaccine from placebo recipients was Gag amino acid 84, a site encompassed by several epitopes contained in the vaccine and restricted by human leukocyte antigen (HLA) alleles common in the study cohort. Moreover, the extended divergence was confined to the vaccine components of the virus (HIV-1 Gag, Pol and Nef) and not found in other HIV-1 proteins. These results represent what is to our knowledge the first evidence of selective pressure from vaccine-induced T cell responses on HIV-1 infection in humans.
At a glance
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008). et al.
- HIV-1 vaccine–induced immunity in the test-of-concept STEP Study: a case-cohort analysis. Lancet 372, 1894–1905 (2008). et al.
- HIV Sequence Compendium 2005 648 and viii (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 2006). et al.
- Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 62, 378–384 (2003). et al.
- HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 4, e6687 (2009). et al.
- Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37, 2419–2433 (2007). et al.
- HIV Molecular Immunology (Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, 2006/2007). et al.
- Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc. Natl. Acad. Sci. USA 102, 4512–4517 (2005). et al.
- Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27–restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375–386 (2001). et al.
- Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27–positive long-term-nonprogressing child. J. Virol. 78, 8927–8930 (2004). et al.
- Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212–217 (1997). et al.
- Timing of immune escape linked to success or failure of vaccination. PLoS ONE 5, e12774 (2010). et al.
- HIV-1 Group M conserved elements vaccine. PLoS Pathog. 3, e157 (2007). , &
- Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25, 533–543 (2006).
- Prediction of MHC-peptide binding: a systematic and comprehensive overview. Curr. Pharm. Des. 15, 3209–3220 (2009). &
- Leveraging information across HLA alleles/supertypes improves epitope prediction. J. Comput. Biol. 14, 736–746 (2007). , &
- HIV-specific probabilistic models of protein evolution. PLoS ONE 2, e503 (2007). et al.
- Genome scanning tests for comparing amino acid sequences between groups. Biometrics 64, 198–207 (2008). , &
- A modified Bonferroni method for discrete data. Biometrics 46, 515–522 (1990).
- Supplementary Text and Figures (2M)
Supplementary Methods, Supplementary Results, Supplementary Tables 1 and 2 and Supplementary Figures 1–5